Advancing the management of HER2-altered NSCLC: Interpreting the latest clinical trial data

touchCONGRESS for touchONCOLOGY and touchRESPIRATORY   Listen to thoracic oncologist Dr. Julia Rotow (USA) review the latest HER2-targeted therapy data for NSCLC from the 2026 ASCO Annual Meeting. Alongside Prof. David Planchard (France) and Dr. Misako Nagasaka (USA), they discuss these findings in the context of evidence presented at recent international congresses and their clinical implications for managing HER2-altered NSCLC. The experts Dr. Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA Prof. David Planchard, Institut Gustave Roussy, Paris, France Dr. Misako Nagasaka, University of California, Irvine (UCI) Health Chao Family Comprehensive Cancer Center, Orange, CA, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from AstraZeneca.  This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchoncology.com or www.touchrespiratory.com